BAY876 , ≥98%(HPLC) , 1799753-84-6
Synonym(s):
N4-[1-[(4-Cyanophenyl)methyl]-5-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]-7-fluoro-2,4-quinolinedicarboxamide
| Pack Size | Price | Stock | Quantity |
| 5mg | RMB719.20 | In Stock |
|
| 10mg | RMB1295.20 | In Stock |
|
| 25mg | RMB2671.20 | In Stock |
|
| 50mg | RMB4799.20 | In Stock |
|
| 100mg | RMB7103.20 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | >250oC (dec.) |
| Boiling point: | 632.3±55.0 °C(Predicted) |
| Density | 1.48±0.1 g/cm3(Predicted) |
| storage temp. | 2-8°C |
| solubility | DMSO (Slightly), Methanol (Slightly) |
| form | powder |
| pka | 10.33±0.70(Predicted) |
| color | white to beige |
Description and Uses
BAY-876 is a potent, highly selective, cell-permeable inhibitor of glucose transporter GLUT1. It had an IC50 value of 2 nM in vitro and inhibited glucose uptake by Hela-MaTu cells with an IC50 value of 3.2 nM. BAY-876 was at least 130-fold selective for GLUT1 relative to GLUT2, GLUT3, GLUT4 and a panel of 18 kinases and 68 proteins.BAY-588 is used as a negative control and is available from Sigma.
BAY-876 is a potent and selective inhibitor of glucose transporter 1 (Glut1) with IC50 values of 2, 10,800, 1,670, and 290 nM for Glut1, Glut2, Glut3, and Glut4, respectively, in CHO cells expressing human recombinant receptors.1 It shows low metabolic clearance and has high permeability in vitro. In vivo, BAY-876 displays low plasma clearance and high oral bioavailability in rats and dogs.
